Does pulmonary rehabilitation address cardiovascular risk factors in patients with COPD? by Gale, Nichola S et al.
RESEARCH ARTICLE Open Access
Does pulmonary rehabilitation address
cardiovascular risk factors in patients with COPD?
Nichola S Gale
1, James M Duckers
2, Stephanie Enright
1, John R Cockcroft





Background: Patients with COPD have an increased risk of cardiovascular disease. Whilst pulmonary rehabilitation
has proven benefit for exercise tolerance and quality of life, any effect on cardiovascular risk has not been fully
investigated. We hypothesised that pulmonary rehabilitation, through the exercise and nutritional intervention,
would address these factors.
Methods: Thirty-two stable patients with COPD commenced rehabilitation, and were compared with 20 age and
gender matched controls at baseline assessment. In all subjects, aortic pulse wave velocity (PWV) an independent
non-invasive predictor of cardiovascular risk, blood pressure (BP), interleukin-6 (IL-6) and fasting glucose and lipids
were determined. These measures, and the incremental shuttle walk test (ISWT) were repeated in the patients who
completed pulmonary rehabilitation.
Results: On commencement of rehabilitation aortic PWV was increased in patients compared with controls (p <
0.05), despite mean BP, age and gender being similar. The IL-6 was also increased (p < 0.05). Twenty-two patients
completed study assessments. In these subjects, rehabilitation reduced mean (SD) aortic PWV (9.8 (3.0) to 9.3 (2.7)
m/s (p < 0.05)), and systolic and diastolic BP by 10 mmHg and 5 mmHg respectively (p < 0.01). Total cholesterol
and ISWT also improved (p < 0.05). On linear regression analysis, the reduction in aortic PWV was attributed to
reducing the BP.
Conclusion: Cardiovascular risk factors including blood pressure and thereby aortic stiffness were improved
following a course of standard multidisciplinary pulmonary rehabilitation in patients with COPD.
Keywords: COPD pulmonary rehabilitation, arterial stiffness
Background
Chronic obstructive pulmonary disease (COPD) is an
increasing cause of global morbidity and mortality [1] of
which cardiovascular (CV) disease accounts for approxi-
mately 30% of the excess mortality in patients [2]. Such
patients have multiple risk factors for CV disease includ-
ing exposure to significant cigarette smoke, physical
inactivity and metabolic disorders [3]. In addition, arter-
ial stiffness measured by aortic pulse wave velocity
(PWV) is an independent predictor of CV risk [4,5],
which is increased in patients with COPD [6].
In the general population, addressing physical activity
and nutritional optimisation, both components of multi-
disciplinary pulmonary rehabilitation, are associated
with reducing the CV risks such as blood pressure (BP)
and cholesterol [7]. Exercise, through biochemical,
neural and hormonal alterations appear to improve vas-
cular function and hence BP [8].
Demonstrable improvements in aortic PWV have been
shown in non-COPD populations with short-term aero-
bic exercise training [9,10], however, the long-term ben-
efits have not been established. In patients with COPD,
a recent small study, demonstrated that four weeks of
endurance exercise training reduced brachial artery
PWV [11]. However, this peripheral measure has not
been established as an independent CV prognostic fac-
tor [12], and the more robust aortic PWV which was
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any medium, provided the original work is properly cited.not measured. Additionally, this was an isolated exercise
intervention.
Multidisciplinary pulmonary rehabilitation is integral
to the management of patients with COPD. Although
the programme is short term, encompassing exercise,
education and nutritional advice, its aim is to address
lifestyle modification and several endeavours are cur-
rently addressing how benefits can be maintained.
Demonstrable benefits in exercise capacity and quality
of life are evident with improvements seen at 1 or 2
years following the course, even without a maintenance
arm [13,14]. Whilst a range of overt co-morbidities are
reported in patients entering rehabilitation, other than
osteoporosis, they appear to exert little detriment to the
standard outcome measures [15,16]. But how rehabilita-
tion might address the CV co-morbidity has not been
explored. We hypothesised that rehabilitation would
improve the increased aortic PWV in patients with
COPD (but with no overt CV disease or diabetes)
together with blood pressure and other CV risk factors.
Methods
Study Design
The design was a prospective cohort study. Patients
meeting the inclusion and exclusion criteria were
recruited consecutively from the routine rehabilitation
referral list at University Hospital Llandough. At base-
line they were compared with control subjects who
attended for one assessment only.
Participants
Thirty-two patients with confirmed COPD, accepted for
rehabilitation were recruited. Patients were clinically
stable, defined as no change in dyspnoea, cough or spu-
tum beyond day-to-day variability; or requirement for
antibiotic or oral corticosteroid therapy in the preceding
month. Subjects were excluded from the study (but not
rehabilitation) if they had known ischaemic heart dis-
ease, cardiac failure, diabetes mellitus, malignancy, or
any other inflammatory or metabolic condition, or were
receiving oral corticosteroids, disease modifying or
weight loss drugs. Twenty age- and sex-matched seden-
tary controls free from respiratory disease and other
exclusions as above, but with a history of cigarette
smoking were also recruited. Controls were spouses of
patients or past volunteers who had agreed to consider
future research. All subjects gave written, informed con-
sent and the study had South East Wales Research
Ethics Committee approval: 07/WSE04/05.
Pulmonary Rehabilitation
The multidisciplinary pulmonary rehabilitation pro-
gramme has been detailed previously [17]. Briefly, it is
outpatient based, thrice weekly over seven weeks, with
sessions lasting 2.25 hours. Each session comprises an
educational element, aerobic and strength training,
nutritional and behavioural therapy as well as relaxation
technique and smoking cessation. A dietician provides
individualised counselling and advice as well as group
sessions to address weight loss, healthy diet or weight
gain, as appropriate to the patient. Standard assessments
include the St Georges respiratory questionnaire
(SGRQ) [18], and the incremental shuttle walk test
(ISWT), following a practice attempt. The ISWT was
used to set the intensity of exercise training at 60-70%
VO2 peak [19]. Patients who are on long-term oxygen
therapy (LTOT) exercised with oxygen as per standard
pulmonary rehabilitation conduct. Following rehabilita-
tion, all patients are encouraged to continue exercise
and opportunities exist at local leisure centres for
patients to attend classes for respiratory patients.
Study Procedures
Anthropometry and Lung Function
For all participants, height (m) and weight (kg) were
measured barefoot, wearing lightweight clothing and
body mass index (BMI) was calculated. All participants
performed spirometry (Vitalograph, UK) to determine
forced expiratory volume in 1 second (FEV1), forced
vital capacity (FVC) and their ratio (FEV1/FVC) accord-
ing to guidelines [20]. Patients were classified according
to the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) criteria for severity of airway obstruc-
tion [1]. Resting oxygen saturations were recorded using
a pulse oximeter (Pulsox-3iA, Konica-Minolta, Japan).
All subjects self-completed a physical activity question-
naire [21].
Haemodynamics
Subjects were assessed having fasted and abstained from
caffeine, tobacco and inhaled short-acting b2 agonists
for at least 6 hours. Peripheral systolic and diastolic BP
was determined at the left brachial artery, and used to
calculate mean arterial pressure (MAP) and pulse pres-
sure (PP) (OMRON Corporation, Kyoto, Japan). Appla-
nation tonometry using a high fidelity micromanometer
(Millar Instruments Texas) was used to measure pulse
waveforms at the radial, carotid and femoral sites, in
relation to the R wave of a simultaneous ECG recording
(SphygmoCor; AtCor Medical, Sydney, Australia). The
radial pulse wave was used to generate a central arterial
waveform, and augmentation index (AIx) was calculated
as the difference between the first and reflected systolic
peak as a percentage of pulse pressure, corrected to a
heart rate of 75 beats per minute. Using integral soft-
ware aortic (carotid - femoral) and brachial (carotid-
r a d i a l )P W Vw a sc a l c u l a t e da st h es p e e do ft h ep u l s e
wave travelling between the 2 sites. Increased PWV and
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aortic PWV being the preferable measure in this age
group [5]. Prior to commencing pulmonary rehabilita-
tion the reliability of the arterial stiffness measurements
were tested in a subset of 19 patients. Assessments were
repeated with a time interval of 1-3 weeks. Coefficients
of reliability for aortic PWV were 0.90 and the intraclass
correlation coefficients were 0.898. For brachial PWV,
these values were 0.79 and 0.757 respectively and for
AIx, 0.67 and 0.547. All assessments were completed by
a single investigator, and waveforms were reviewed by
an independent operator to verify quality and
consistency.
Biochemistry
A sample of venous blood was taken following the hae-
modynamic assessment, but prior to any exertion. Fast-
ing glucose and cholesterol were determined within the
Trust biochemistry laboratory according to standard
procedure. Interleukin (IL)-6 was determined by ELISA
(R&D Systems Europe, Abingdon, UK) with a minimum
detectable limit of less than 0.70 pg/mL [22].
Data Analysis
Data analysis was performed using the Statistical Pack-
age for the Social Sciences (SPSS, Chicago, IL), version
16.0. Skewed data were log10 transformed and checked
for normality prior to analysis. Data are presented as
mean and standard deviation (SD) unless stated.
Patients and controls were compared using an
unpaired t test and the chi squared test for categorical
data. Relationships were investigated using Pearson’s
correlations.
Assessments pre and post rehabilitation were analysed
using the paired t test for parametric data and linear
regression was used evaluate the contribution of change
in blood pressure to change in aortic PWV. The signifi-
cance level for all statistical tests was set at p < 0.05.
T h es a m p l es i z ew a sb a s e do np r e v i o u sp u b l i s h e dw o r k
from the department in patients with COPD [6]. For an
80% power, with a p < 0.05, 22 patients were required
to detect a 15% reduction in aortic PWV from 11.4 m/s
with a SD of 2.7 m/s.
Results
Patients and controls were similar with respect to age,
sex and BMI (Table 1). All participants had a history of
cigarette smoking of at least 5 smoking pack-years. Five
patients and two controls were current smokers and
patients had a greater pack-year exposure. As expected,
patients had impaired pulmonary function and lower
resting oxygen saturations (p < 0.05). The mean PaO2 in
patients at room air was 70 (10)mmHg, 4 patients were
on LTOT and had been stabilised on this prior to
commencement of rehabilitation. Thirteen patients clas-
sified as GOLD stage II and 19 patients were stage III/
IV [1].
Of the 32 patients recruited at baseline, 31 (97%) of
patients were taking a short-acting b2-agonist, 5 (16%)
were taking a long-acting b-agonist alone, 25 (78%)
were on combination inhaled therapy (long-acting b-
agonist & corticosteroid), 30 (94%) were taking an antic-
holinergic bronchodilator.
Eight patients (25%) and four control subjects (20%)
were taking antihypertensive medication, while five
patients (16%) and six controls (30%) had been pre-
scribed statins for hypercholesterolaemia. There were no
other cardiac medication and there was no change to
CV or respiratory maintenance medication was made
during rehabilitation.
At Commencement of Rehabilitation
Haemodynamic and Metabolic Data
Patients with COPD had greater aortic PWV than con-
trols (p < 0.05) despite having similar MAP. There were
13 (41%) patients, 4 of whom were on prior treatment
had a BP greater than the recommended, with either a
systolic >140 or diastolic >90 mmHg. In parallel, 5
(25%) controls, 2 on treatment, also had elevated BP.
Heart rate and IL-6 were also greater in patients than
controls (Table 2). Although mean levels of glucose and
lipids were similar between patients and controls, more
patients had levels of total cholesterol above the optimal







Age (years) # 64 (51-81) 65 (49-80) 0.730
Gender (male%) 7 (35%) 11 (34%) 0.964
Height (m) 1.67 (0.09) 1.62 (0.09) 0.083
Weight (kg) 74.1 (15.9) 67.0 (19.0) 0.166
BMI (kg/m
2) 26.5 (3.9) 25.4 (6.4) 0.521
Smoking pack-years # 15 (5-50) 40 (5-90) <0.001
Current smokers 2 (10%) 5 (15%) 0.595
FEV1 (L) 2.72 (0.66) 0.99 (0.39) <0.001
FEV1 (% predicted) 108 (14) 45 (20) <0.001
FVC (L) 3.50 (0.91) 2.18 (0.68) <0.001
FVC (% predicted) 114 (13) 78 (22) <0.001
FEV1/FVC 0.78 (0.06) 0.46 (0.15) <0.001
SpO2 (%) # 97 (94-97) 96 (85-96) <0.01
Physical Activity Score
(METs)#
38 (28-78) 31 (25-58) <0.001
Data presented as mean (SD), unless # = median (range).
*p < 0.05 and **p < 0.01 difference between baseline patients and control
subjects
Abbreviations: BMI = body mass index; FEV1 = forced expiratory volume in 1
second; FVC = forced vital capacity; METs = metabolic equivalents; SpO2 =
oxygen saturations pulse oximetry.
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compared with controls 10 (50%) [23].
Anthropometry
Although mean BMI was similar in patients with COPD
and control subjects, BMI was more heterogeneous in
the patients. Six patients (no controls) were underweight
(BMI <20 kg/m
2), and 8 patients (3 controls) were obese
(BMI ≥30 kg/m
2) [24].
In all subjects and in patients alone, as expected, aor-
tic PWV was related to age (r = 0.579 and r = 0.593
respectively, both p < 0.001); as well as aortic PWV
related to central and peripheral systolic BP and periph-
eral MAP (all p < 0.05). Aortic PWV did not relate to
other clinical variables; FEV1, oxygen saturations or
smoking pack-years. Although patients reported less
physical activity in the preceding month than controls
this was not related to aortic PWV.
The Effect of Pulmonary Rehabilitation
Of the 32 patients, 22 completed rehabilitation - for this
group of completers, median (range) number of atten-
dances was 18 (14-20) out of 20. There was no difference
in age, gender, baseline lung function, haemodynamic vari-
ables or body composition between patients who com-
pleted study assessments and those who did not. Reasons
for non-completion were illness, personal constraints or
exclusion from the study due to commencement of oral
corticosteroids. One of the five patients who smoked at
baseline stopped smoking during rehabilitation.
Following rehabilitation aortic PWV reduced from
9.8 (3.0) to 9.3 (2.7) m/s (p < 0.05) (Figure 1) and per-
ipheral BP decreased markedly (all p < 0.05) (Table 3).
Using linear regression, following adjustment for the
change in central MAP the improvement in aortic
PWV was attenuated. The reduction in BP occurred in
both patients who had an elevated BP (11/22 had ele-
vated BP) and those who commenced with a BP within
the recommended range. Following rehabilitation, 3 of
the 11 patients with high BP at baseline no longer met
the criteria for hypertension at completion despite no
change in pharmacological therapy. There was a mod-
est reduction in total cholesterol (5.6 (1.2) to 5.4 (1.1)
mmol/L p < 0.05), and 2 of the 15 patients no longer
met the criteria for high cholesterol after rehabilitation.
Brachial PWV and AIx were unchanged with
rehabilitation.
Overall there was no change in glucose, IL-6 or BMI.
However as expected, traditional rehabilitation outcome
measures - ISWT and SGRQ improved, although these
did not relate to change in aortic PWV. There were 19/
22 patients who exceeded the minimum clinically signif-
icant improvement of 47.5 m [25] and 17 patients
exceeded the minimum clinically significant difference
of 4 units for total SGRQ score [18].
Table 2 Baseline haemodynamic and metabolic data in






Aortic PWV (m/s) 8.5 (1.4) 9.8 (2.7) <0.05
Brachial PWV (m/s) 8.5 (1.2) 9.0 (1.7) 0.329
AIx (%) 26.9 (15.9) 32.3 (8.4) 0.156
Peripheral SBP (mmHg) 130 (16) 138 (19) 0.135
Peripheral DBP (mmHg) 79 (8) 82 (9) 0.247
Peripheral PP (mmHg) 51 (13) 56 (15) 0.196
Peripheral MAP (mmHg) 96 (10) 100 (11) 0.177
Central SBP (mmHg) 120 (16) 125 (18) 0.368
Central DBP (mmHg) 80 (8) 82 (11) 0.621
Central PP (mmHg) 40 (12) 47 (18) 0.133
Central MAP (mmHg) 97 (10) 104 (13) 0.055
Heart rate (bpm) 68 (11) 77 (12) <0.01
Fasting Glucose (mmol/L) 5.2 (0.5) 5.0 (0.6) 0.236
Total Fasting Cholesterol (mmol/L) 5.2 (1.2) 5.6 (1.2) 0.360
LDL (mmol/L) 3.0 (1.2) 3.3 (1.1) 0.322
HDL (mmol/L) 1.6 (0.7) 1.7 (0.5) 0.504
Cholesterol/HDL ratio 3.8 (1.5) 3.5 (1.0) 0.373
Triglyceride (mmol/L) 1.2 (0.6) 1.1 (0.4) 0.591
IL-6 † (pg/ml) 1.3 (3.1) 3.8 (2.1) <0.001
Data presented as mean (SD), unless otherwise stated, † = Geometric mean.
Abbreviations: AIx = augmentation index; DBP= diastolic blood pressure; HDL
= high-density lipoprotein; IL-6 = interleukin 6; LDL = low-density lipoprotein;
MAP = mean arterial pressure; PP = pulse pressure; PWV = pulse wave
velocity; SBP = systolic blood pressure.
Figure 1 Change in Aortic Pulse Wave Velocity and Mean
Arterial Pressure with Pulmonary Rehabilitation in patients
with COPD. Solid lines represent the change in aortic pulse wave
velocity (PWV), triangles denote the mean change in aortic PWV.
Dotted lines show the change in mean arterial pressure (MAP),
diamonds indicate mean change in MAP.
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This is the first study to evaluate the effect of a standar-
dised multidisciplinary pulmonary rehabilitation pro-
gramme on central arterial haemodynamic risk factors in
patients with COPD. Pulmonary rehabilitation improved
several cardiovascular risk factors including aortic PWV,
an independent predictor of CV risk in the general popu-
lation, blood pressure and cholesterol [4,5]. A recent
study of four weeks of endurance cycling, in ten patients
with COPD, demonstrated improved peripheral arterial
stiffness measured by brachial PWV in improved second-
ary to systolic BP improvement [11]. In comparison, the
seven untrained patients had no significant haemody-
namic change. Our findings corroborate this study using
the ‘gold standard’ aortic PWV as the primary variable,
with exercise being part of a pulmonary rehabilitation
programme, which is already integrated in COPD man-
agement. Similar to Vivodtzev et al, we demonstrated a
reduction in systolic BP with the intervention and the
fact that systolic BP explained the reduction in aortic
PWV does not detract from the actual improvement of
aortic stiffness, whatever the mechanism with pulmonary
rehabilitation. There was no change in brachial PWV or
AIx found which may be a consequence of the different
properties of central and peripheral arteries, nor were
either markedly increased compared to controls in the
present study and both are inferior measurements to aor-
tic PWV in this age group of subjects [5,12].
The clinical relevance of the change in aortic PWV in
this study is uncertain as a clinically significant reduc-
tion has yet to be fully established. Certainly, an increase
in aortic PWV of 1 m/s corresponds to an adjusted risk
increase of 15% in CV mortality [26], but the reverse is
less clear. A 10 mmHg reduction in systolic BP is likely
to improve CV risk - a recent meta-analysis of pharma-
cological intervention, showed using a meta-regression
analysis, that a 5 mmHg reduction in systolic BP equa-
ted to a 13% reduction in risk of CV death, myocardial
infarction or stroke [27].
Although limited data exists in subjects with COPD,
the haemodynamic benefits of aerobic exercise have been
demonstrated in non-respiratory conditions. In subjects
with hypertension 4 weeks of exercise resulted in a 9%
r e d u c t i o ni na o r t i cP W V[ 2 8 ] .T h i si ss o m e w h a th i g h e r
than the present study but may be explained by a
younger population, without respiratory impairment. The
antihypertensive effects of aerobic exercise have been
well established in both normotensive and hypertensive
individuals using standard brachial sphygomanometry
[29]. Additionally, cardiac rehabilitation, which provides
exercise and lifestyle modification to cardiac patients has
been shown to reduce BP and cholesterol [30]. All of
these studies support the short-term reduction in CV
risk factors demonstrated with pulmonary rehabilitation
in this present study of patients with COPD.
The mechanism of improved haemodynamics follow-
ing exercise has not been established, but may include
increased shear stress with improved structural compli-
ance, nitric oxide related vasodilation and reduced sym-
pathetic drive [31]. The latter potential mechanism was
reported in patients with COPD after six weeks of aero-
bic exercise training [32], but the effects on BP were not
recorded. In non-COPD individuals with hypertension,
exercise training decreased BP along with reduced vas-
cular resistance and sympathetic nervous activity [29].
We and others have previously reported increased
arterial stiffness in patients with COPD compared to
controls [6,33,34]. It was important however, to confirm
if this was seen in the selected patients referred to reha-
bilitation compared to previous reported groups of
COPD patients [6,28,29]. Why patients with COPD have
increased aortic PWV has not been fully established,
however they have multiple risk factors for CV disease
including a history of cigarette smoking, physical inac-
tivity, nutritional and metabolic abnormalities as well as
airflow obstruction [35]. As in the general population
we report aortic PWV was related to age and BP in
both patients and in the whole subject group. However,
aortic PWV was greater in patients compared to age








Aortic PWV (m/s) 9.8 (3.0) 9.3 (2.7) <0.05
Brachial PWV (m/s) 9.0 (1.7) 8.9 (1.6) 0.535
AIx (%) 33.9 (5.3) 33.6 (8.8) 0.833
Peripheral SBP (mmHg) 138 (20) 128 (24) <0.01
Peripheral DBP (mmHg) 83 (9) 78 (12) <0.01
Peripheral PP (mmHg) 55 (15) 49 (19) <0.05
Peripheral MAP (mmHg) 101 (12) 95 (14) <0.001
Central SBP (mmHg) 126 (21) 120 (23) <0.05
Central DBP (mmHg) 83 (12) 79 (12) <0.05
Central PP (mmHg) 43 (14) 41 (18) 0.471
Central MAP (mmHg) 103 (14) 95 (14) <0.001
Heart Rate (bpm) 76 (12) 76 (14) 0.933
Fasting Glucose (mmol/L) 5.0 (0.7) 4.8 (0.8) 0.079
Total Fasting Cholesterol
(mmol/L)
5.6 (1.2) 5.4 (1.1) <0.05
LDL (mmol/L) 3.4 (1.1) 3.3 (1.2) 0.389
HDL (mmol/L) 1.7 (0.5) 1.6 (0.4) 0.050
ISWT (m) 190 (70) 274 (76) <0.001
SGRQ Total Score 56.5 (13.9) 44.9 (16.1) <0.001
Data presented as mean (SD)
Abbreviations: AIx = augmentation index; DBP= diastolic blood pressure; HDL
= high-density lipoprotein; IL-6 = interleukin 6; ISWT = Incremental shuttle
walk test; LDL = low-density lipoprotein; MAP = mean arterial pressure; PP =
pulse pressure; PWV = pulse wave velocity; SBP = systolic blood pressure;
SGRQ = St Georges respiratory questionnaire.
Gale et al. BMC Pulmonary Medicine 2011, 11:20
http://www.biomedcentral.com/1471-2466/11/20
Page 5 of 7matched controls in the setting of a similar MAP, hence
suggesting that there are other contributing factors.
Aortic PWV has previously been associated with
impaired lung function in both COPD subjects [6] and a
general population of men [36]. Pulmonary function has
also been associated with risk factors for metabolic dis-
ease [37,38], which appears to be at increased prevalence
in patients with COPD [39]. An increased systemic
inflammatory state is characteristic in COPD, and has
been related to increased CV risk in the general popula-
tion. In this study, the inflammatory mediator IL-6 was
increased in patients with COPD, but it was not attenu-
ated by rehabilitation, concurring with previous reports
of rehabilitation intervention [40].
The limitations of this study include the small sample
size and a high rate of drop out from the study over the
course of pulmonary rehabilitation. Whilst we still met
our sample size, the mean aortic PWV at baseline was
lower than previously reported and which was used in our
power calculation [6], perhaps reflecting the characteristics
of a subgroup of patients with COPD who are deemed sui-
table for pulmonary rehabilitation, but additionally a larger
proportion were female. This lower baseline value is likely
to, at least partially, account for why we did not see the
reported 15% change in aortic PWV with rehabilitation.
The study could be criticised for the inclusion of patients
and controls with hypertension however, where feasible,
we tried to mimic patients entering the standard pulmon-
ary rehabilitation programme whilst excluding clear con-
founders such as prior ischaemic heart disease or diabetes.
It is plausible that adherence to the pulmonary rehabilita-
tion programme could have improved adherence to medi-
cation in general given pulmonary rehabilitation focuses
on lifestyle factors. No control COPD group was included
as it would not have been ethical to deny patients with
COPD access to pulmonary rehabilitation. Considering
conducting a “comparable” course for the controls encom-
passing the multidisciplinary aspects of rehabilitation,
whilst ideal, was open to several other confounders, not
least trying to equate the exercise across courses. It was
not possible to match smoking exposure between patients
and controls. However, Maclay and colleagues has already
reported the difference in aortic PWV between matched
smokers with and without COPD [34]. The change in hae-
modynamics appeared across the range at baseline, point-
ing away from regression to the mean. Having presented
these findings, assessment of haemodynamics before and
after pulmonary rehabilitation on a larger scale is required.
Conclusion
This study confirms the presence of multiple cardiovascu-
lar risk factors in patients with COPD undergoing multi-
disciplinary pulmonary rehabilitation, and is the first to
show that a standardised programme appears to improve
the cardiovascular risk profile. Pulmonary rehabilitation
may be an opportunity to identify and treat cardiovascular
and metabolic dysfunction and therefore may provide
additional benefit lead to patients. Further research is
required to corroborate and determine the longer term
implications of these haemodynamic changes. The clinical
impact of the findings reported is potentially transferable
across rehabilitation programmes and reinforces the
known functional and health status improvements that
pulmonary rehabilitation already delivers.
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